LED Medical Diagnostics Announces Launch of RAYSCAN Alpha Plus Imaging System from RAY Company

New Extraoral Multi-Modality Dental Imaging System Boasts Exclusive Variable Light-Guided Field-of-View Combined with Lightning Fast Image Reconstruction
Vancouver, BC - September 28, 2016 - LED Medical Diagnostics Inc., through its wholly-owned US and Canadian operating subsidiaries, LED Dental Inc./LED Dental Ltd. ("LED Dental") is pleased to announce the launch of the RAYSCAN Alpha Plus, a next-generation extraoral imaging system that is the latest innovation from former Samsung Electronics subsidiary RAY Company ("RAY").

Building upon the award-winning RAYSCAN Alpha platform, the RAYSCAN Alpha Plus continues RAY Company's dedication to delivering high-quality imaging technologies combined with innovative features that break new ground in the industry.

Clinicians can utilize the RAYSCAN Alpha Plus to capture high-resolution panoramic, cephalometric and cone beam computed tomography images. The panoramic modality allows for a variety of 2D panoramic examinations, including standard pano and segmented pano acquisitions, in addition to an extraoral bitewing feature.

The CBCT modality of the RAYSCAN Alpha Plus boasts several exclusive features that allow practitioners to truly customize examinations to their patients unlike ever before. First, the Alpha Plus utilizes an innovative light-guided field-of-view that simplifies patient positioning to reduce errors and retakes. The desired field-of-view is super-imposed on the patient’s face, allowing dental professionals to see the exact area being scanned in relation to the patient’s actual anatomy, ensuring accurate image acquisition.

Furthermore, the system adds to the innovative light-guided positioning feature by utilizing Free FOV technology, which makes the field-of-view completely customizable from 4x3 cm to 16x10 cm. While many systems on the market force the clinician to choose one of several pre-set field-of-view options, the RAYSCAN Alpha Plus allows practitioners to collimate the field-of-view to any size, truly limiting radiation exposure to the smallest area possible to still acquire the needed anatomy.

While The RAYSCAN Alpha Plus continues to push new boundaries in terms of dose reduction, image quality and clarity remain the system’s top priority. The CBCT modality delivers voxel resolutions as small as 70 microns, making 3D images from the RAYSCAN Alpha Plus among the highest resolution in the industry. And, new proprietary algorithms allow for images to be reconstructed in as little as 4.9 seconds.

Finally, the optional cephalometric module is available in either scanning or one-shot options, with the one-shot module acquiring images in less than one second to further reduce image distortion and lessen radiation dose.

"We could not be more excited to launch the RAYSCAN Alpha Plus in conjunction with our partners at RAY Company," stated Dr. David Gane, CEO of LED Medical Diagnostics. "Over the last few years, RAY Company has illustrated a commitment to developing technologies that not only deliver exceptional image quality, but also integrate innovative features that make acquiring images more intuitive, delivering an improved user experience while reducing patient dose."

Kevin Cho, President of RAY America concluded, "The RAYSCAN Alpha Plus is the culmination of years of development and optimization, relying on clinical feedback to build a system that not only produces outstanding images but utilizes next-generation technologies to make oral healthcare a simpler, more patient-friendly process."

The RAYSCAN Alpha Plus is available now through LED Dental. For more information, please call 844.952.7327 or visit www.leddental.com.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Vancouver, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc. and LED Dental Ltd, provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.

The Company is currently listed on the TSX Venture Exchange (TSX-V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, call 844.952.7327 or visit www.leddental.com/investor-relations.

About RAY Company, Ltd.

Since 2004, RAY has specialized in researching, developing and producing high-quality digital imaging systems for the medical and dental industries. Due to the company’s development of superior imaging technologies, RAY became a subsidiary of worldwide technology leader Samsung Electronics Co., Ltd, in 2010. Under the Samsung brand, RAY Company launched the RAYSCAN Alpha - Expert in 2012 and rapidly penetrated the US market beginning in 2014. With the success of the RAYSCAN Alpha, RAY made the strategic decision to become an independent imaging company in 2015, singularly focused on its future as a leader in the worldwide dental imaging market.  Learn more at www.rayamerica.com.

LED Medical Diagnostics

Investor Relations:

Bristol Capital
Glen Akselrod
Phone: 905.326.1888, ext. 10
Email: glen@bristolir.com

Media Contact:

LED Dental
Chris Koch
Phone: 678.293.9413
Email: chris.koch@leddental.com

Corporate Contact:

LED Medical
David Gane, CEO
Phone: 604-434-4614 x227
Email: david.gane@leddental.com

Forward Looking Statement

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future growth strategy, its distribution strategy and product offerings, potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2015. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.